Purpose of this study was to evaluate feasibility of thoracic radiotherapy (TRT) with concurrent daily low-dose carboplatin for inoperable stage III NSCLC in elderly or frail patients in the Central European population. Modified Japanese treatment protocol originally published by Atagi et al (Jpn J Clin Oncol, 30, 2, 59-64) was used. TRT 60 Gy (2 Gy fractions, 5 days a week) was administered over a 6-week period. Carboplatin 25 mg/m2 as a 30 min infusion was given one hour before TRT, daily, over four weeks, starting on day one. The eligibility criteria for patients included: age 65 years or over with ECOG PS 0 – 2 or younger with ECOG PS 2, histologically and/or cytologically confirmed NSCLC, inoperable stage III disease, satisfactory blood count and standard biochemical parameters. There was no age-limit. Twenty patients were treated. Patients' characteristics: elderly/non-elderly: 18/2, age – median: 73.5 years (range: 55 – 80), male/female: 18/2, ECOG PS 0/1/2: 0/10/10, squamous cell carcinoma/adenocarcinoma: 18/2. All patients were assessable for treatment response and toxicity. In fourteen was it possible to administer the entire protocol therapy without any disruption. The response by the end of treatment was: complete response: 0, partial response: 12 (60%; 95%CI: 39 – 78%), stable disease: 7 (35%; 95%CI: 18 – 57%), progressive disease: 1 (5%; 95%CI: 1 – 24%). Survival time – median: 19 months (range: 3 – 36+; 95%CI: 10 – 26), 2-year survival rate – 35% (95%CI: 18 – 57%). Main toxicities were as follows: NCI CTC grade 3/4 neutropenia in 25/5%, thrombocytopenia in 15/5%, febrile neutropenia in 5/0%, respiratory infection in 10/0%, and esophagitis in 5/0%. Transfusions and/or erythropoietin were given due to grade 2 anemia in 40% of patients. All toxicities were manageable and there was no treatment related death. TRT with daily low-dose carboplatin was feasible in our group of patients. Response rates and survival are comparable with those achieved in younger good prognosis patients by more sophisticated combinations of TRT and chemotherapy.